Physicians' Academy for Cardiovascular Education

SGLT2i reduces risk of kidney and CV outcomes across subgroups of baseline UACR

News - Oct. 4, 2021

Efficacy and safety of dapagliflozin on kidney and cardiovascular outcomes by baseline albuminuria: a secondary analysis of the DAPA-CKD trial

Presented at the EASD 2021 by: Prof. Hiddo Lambers Heerspink, MD - Groningen, The Netherlands

Introduction and methods

The DAPA-CKD trial previously showed that the SGLT2 inhibitor dapagliflozin reduced the risk of kidney failure, HF hospitalizations or CV death and all-cause mortality in patients with CKD, with or without T2DM. This prespecified secondary analysis assessed the efficacy and safety of dapagliflozin on kidney and CV outcomes according to baseline albuminuria.

In DAPA-CKD, patients with CKD (UACR 200-5000 mg/g; eGFR 25-75 mL/min/1.73m²) were randomized to dapagliflozin 10 mg/d or placebo. The primary endpoint was a composite of sustained ≥50% decline in eGFR, onset of end-stage kidney disease, or death from a kidney or CV causes. Secondary outcomes included a kidney-specific outcome (primary outcome excluding CV death), CV death or HF hospitalization, and all-cause mortality.

The current analysis assessed the relative and absolute effects of dapagliflozin vs. placebo for primary and secondary outcomes stratified by UACR at baseline (≤1000 mg/g, >1000 to ≤3500 mg/g, >3500 mg/g).

Main results

Conclusion

This prespecified secondary analysis of the DAPA-CKD trial showed that the efficacy and safety of dapagliflozin on kidney and CV outcomes was consistent across subgroups of baseline UACR in patients with CKD with and without T2DM.

-Our reporting is based on the information provided at the EASD Virtual Meeting–

Share this page with your colleagues and friends: